Jason Westin, MD FACP FASCO (@Lymphoma

Jason Westin, MD FACP FASCO

8,167 posts

Jason Westin, MD FACP FASCO

@Lymphoma_Doc

Professor @MDAndersonNews, Lead of Lymphoma/Myeloma Service Line, Director of Clinical Research, Section Chief of Aggressive/Indolent Lymphomas, Opinions mine

Houston, TX

faculty.mdanderson.org/profiles/jason…

Joined January 2013

Pinned
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Apr 17, 2024
I am so honored to receive the @ASCO Advocate of the Year award. Engaging with advocacy is such an important way to support our patients. #ASCOAdvocacySummit
ASCO
@ASCO
Apr 17, 2024
“If we're not advocating…fighting against #drugshortages & for NCI funding & the CONNECT for Health Act, others are advocating the other direction...What you're doing here really matters,” Advocate of the Year @Lymphoma_Doc. Congrats! brnw.ch/21wISP5 #ASCOAdvocacySummit
23K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Sep 1, 2023
Proud to share that I have been promoted to Professor at @MDAndersonnews. I am profoundly grateful for my patients, team, colleagues, collaborators, and mentors. Looking forward to the next steps to #EndCancer
35K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Aug 11, 2022
Big news: our Smart Start trial is now online in @JCO_ASCO! The first trial to show targeted therapy, alone and with chemo, can have excellent outcomes in patients with newly diagnosed DLBCL. A new precedent established! #lymsm
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Dec 11, 2021
Friendly reminder that words matter: Patients do not fail therapies, instead therapies fail patients. #ASH21
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
May 31, 2019
#ASCO19 pro tip: want a copy of a slide from a talk? Don’t hold up your phone for a photo - instead open the iPlanner app, click “interact”, and the slides are shown on your device. Be sure to cite the speaker.
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Nov 8, 2023
Replying to @DGlaucomflecken
This is not a good post. Thousands of doctors do research via clinical trials and take care of patients and write grants and advocate for their patients. Most of your posts are great, but not this one.
163K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Mar 25, 2023
This incredible reporting should result in Congressional hearings where CEOs of @Cigna and other insurance companies should publicly defend this exploitative practice. Sick patients deserve answers from the companies they pay for health insurance. #FixPriorAuth
ProPublica
@propublica
Mar 25, 2023
Doctors at a major US insurance company deny tens of thousands of claims a month without even looking at patients’ files. “We literally click & submit,” a former Cigna doctor told @propublica & @Capitol_Forum. “It takes all of 10 seconds to do 50 at a time.” The inside story 🧵
19K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Apr 1, 2022
Excellent news for our patients: CAR T-cell therapy (axi-cel) is now approved for patients treated in second line for large B-cell lymphoma. My team at ⁦@MDAndersonNews⁩ was honored to play a role in the pivotal result. fda.gov/drugs/resource…
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Jun 21, 2025
Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At @icmlugano, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy
22K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Aug 20, 2025
Grateful for the opportunity to serve on the @ASCO Board of Directors. Looking forward to contributing to the mission of conquering cancer through research, education, and promotion of the highest quality patient care.
connection.asco.org
ASCO Announces Dr. Jason Westin as New Member of Society Board of Directors
ASCO is pleased to welcome Dr. Jason Westin to the Society Board of Directors. Dr. Westin is filling a seat vacated by Dr. Nathan Pennell, who stepped down after accepting a new employment opportunity
7.6K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Jun 5, 2023
ZUMA-7 is the first trial in nearly 30 years to significantly improve overall survival for patients with relapsed/refractory large B-cell in 2L therapy. Thank you to all the patients who participated in this paradigm shifting trial. #ASCO23
NEJM
@NEJM
Jun 5, 2023
Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:
13K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Dec 10, 2022
My annual @ASH_hematology meeting gripes. Add yours #ASH22 1. CR = complete response. Response is categorical, remission is not. 2. Patients do not “fail therapy”, they are “failed by therapy”. #lymsm
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Dec 10, 2024
Wow: Tafasitamab significantly improved outcomes when combined with R-Len in patients with relapsed follicular lymphoma. A new standard of care? Excellent presentation by Dr Sehn of InMind. #ASH24 #lymsm
13K
Jason Westin, MD FACP FASCO
@Lymphoma_Doc
Dec 5, 2023
Thank you @RonWyden & @MikeCrapo and @SenateFinance for the important hearing today on drug shortages. On behalf of @ASCO, I testified “we have life saving drugs, and life threatening shortages”
12K